Loading...
| A14443 | Pages: NA | Jan 2022 | 40 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Cluster Headache Market
Request Now !Cluster headache is a neurological disorder whose exact cause is unknown but studies have shown that it might happen due to abnormality in the body’s biological clock, depicted by the recurrence of severe headache usually around the eye on one side of the head. It is characterized by excessive tears, swelling of the eye, and nasal decongestion. Though the symptoms are similar to that of migraine, people suffering from syndrome might feel agonizing bouts of unilateral headaches, but it is not associated with triggers such as hormonal changes, stress, or even food.
Market Scope and Structure Analysis
Report Metric | Details |
Market Size Available for Years | 2021–2030 |
Base Year Considered | 2020 |
Forecast Period | 2021–2030 |
Forecast Unit | Value (USD) |
Segments Covered | Drug Class, Type, and Region |
Regions Covered | North America, Europe, Asia-Pacific, and LAMEA |
Companies Covered | GlaxoSmithKline plc, Winston Laboratories, ElectroCore Medical LLC, Lundbeck Seattle Biopharmaceutical, Eli Lilly and Company, Autonomic Technologies, Inc., Zosano Pharma, and AstraZeneca Plc. |
Impact of COVID-19 Pandemic on the Cluster Headache Market:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the cluster headache market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish the Market
In 2017, ElectroCore, a medical technology company, announced the launch of gammaCore, a non-invasive vagus nerve stimulator, to treat the acute pain associated with episodic cluster headache in adults.
In 2019, Eli Lilly and Company, an American pharmaceutical company, got the approval of Food and Drug Administration on Galcanezumab (Brand Name: Emgality), an antibody used for migraine as well as cluster headache.
Key Segments Covered
Segment | Subsegment |
Drug Class |
|
Type |
|
Region |
|
Key Benefits of the Report
Questions answered in the cluster headache report
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
